Drugs / FPI-2265
FPI-2265
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07590934 | Jun 2026 → Sep 2029 expected | metastatic prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06909825 | Feb 2025 → May 2027 expected | metastatic prostate carcinoma | Fusion Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06402331 | Mar 2024 → Dec 2026 expected | castration-resistant prostate carcinoma | Fusion Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05219500 | Dec 2021 → May 2025 overdue | castration-resistant prostate carcinoma | Fusion Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07611110 | May 2026 → Feb 2029 expected | prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FPI-2265 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05219500 ↗ |
| Known as | 225Ac-PSMA-I&T | “FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)” NCT06909825 ↗ |
| Known as | AZD2265 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07590934 ↗ |
| Modality | Small molecule | “Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225” NCT05219500 ↗ |
| Route | Intravenous | “FPI-2265 (Dose A intravenously \[IV\] every six weeks)” NCT06909825 ↗ |